Press releases // 13 July 2023
IntegraGen reports €5.6m in revenues for H1 2023 representing 13% decrease compared to H1 2022 and a cash position of €4.3m

Évry, France, Thursday July (…) »
Press releases // 13 July 2023
Évry, France, Thursday July (…) »
Press releases // 24 April 2023
Evry, France, april 24th 2023, 6 pm – IntegraGen (FR0010908723 – ALINT – Eligible PEA PME), IntegraGen, a company specializing in the decryption of the (…) »
Press releases // 13 January 2023
EVRY, FRANCE, FRIDAY JANUARY 13TH 2023, 7.30AM CET – IntegraGen (FR0010908723 – ALINT), an OncoDNA Group company specializing in the decryption of (…) »
Press releases // 18 October 2022
EVRY, FRANCE, TUESDAY OCTOBER 18TH 2022, 7.30AM – IntegraGen (FR0010908723 – ALINT – Eligible PEA PME), IntegraGen, a company specializing in the decryption (…) »
Press releases // 13 July 2022
Evry, France, Wednesday July 13th 2022, 7.30am – IntegraGen (FR0010908723 – ALINT ), an OncoDNA Group company specializing in the decryption of the human genome which performs (…) »
Press releases // 29 April 2022
Évry, France, april 29TH 2022 – 6.00pm (…) »
News // 20 January 2022
IntegraGen and BIOASTER have been collaborating for several years in the context of genomic and transcriptomic analyses. Driven by a desire to strengthen this relationship further, the two entities have entered into a long-term partnership agreement (Master Research Service Agreement). This agreement will facilitate and accelerate exchanges between (…) »